Document is current
Any future updates will be listed below
-
Authors
Fadel, Michael G.
Murray, James
Woodfield, Georgia
Belluomo, Ilaria
Laponogov, Ivan
Parker, Aaron
Converso, Valerio
Ellis, James K.
Wheatstone, Pete
Hepburn, Julie
Groves, Chris
Monahan, Kevin
Saunders, Brian P.
Španěl, Patrik
Veselkov, Kirill
Cross, Amanda J.
Kontovounisios, Christos
Sharples, Linda D.
Hanna, George B.
,
Klimowska-Nassar, Natalia
Ni, Melody
Adade, Claudia
Emerton, James
Ivie, Stephanie
Jameson, Ella
Joy, Lija
Ogunwemimo, Olumayowa
Panda, Anukriti
Richards, Kerry
Speranzini, Elisa
Tofiat, Adebayo
Oblak, Metod
Black, Ethel
Claros, Karmina
Hogan, Holly
Connarty, Sean
Gopi, Parvathy Oby
Raspa, Valentina
Ashton, Julian
Dawson, Annabel
Hoffman, Maurice
Jefford, Monica
Lamouline, Carrol
Smith, Debra
-
Funding
Funding for this research was provided by:
NIHR Doctoral Fellowship programme (NIHR303043)
CW+ and Westminster Medical School Research Trust (JRC FS 001)
Cancer Research UK (EDDPGM-May21\10007)
- License Information
-
More Information
Article History
Received: 30 May 2025
Accepted: 16 June 2025
First Online: 29 July 2025
Declarations
:
: The study has been approved by the East of England—Essex Committee (Ref: 17/EE/0112).
: Not applicable.
: GBH holds patents on volatile biomarkers and founded a diagnostic company for cancer. All other authors have no conflicts of interest to declare.
